Siamak Daneshmand, MD, explores unmet needs in the bladder cancer treatment landscape at ESMO 2023.
ESMO 2023: Updates in Genitourinary Cancers
An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.
Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023.
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.
Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.
An overview of the LITESPARK-003 study of belzutifan from ESMO 2023 and the role of HIF2α inhibitors in renal cell carcinoma (RCC).
Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care.
Advertisement
Advertisement
Trending on AJMC
1
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
2
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
3
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
4
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
5
